Sayuri N Friedland, Aaron Leong, Kristian B Filion, Jacques Genest, Iliana C Lega, Salvatore Mottillo, Paul Poirier, Jennifer Reoch, Mark J Eisenberg
Division of Cardiology, Jewish General Hospital/McGill University, Montreal, Quebec, Canada.
The American journal of medicine 2012 FebAlthough peroxisome proliferator-activated receptor agonists are prescribed to improve cardiovascular risk factors, their cardiovascular safety is controversial. We therefore reviewed the literature to identify landmark randomized controlled trials evaluating the effect of peroxisome proliferator-activated receptor gamma agonists (pioglitazone and rosiglitazone), alpha agonists (fenofibrate and gemfibrozil), and pan agonists (bezafibrate, muraglitazar, ragaglitazar, tesaglitazar, and aleglitazar) on cardiovascular outcomes. Pioglitazone may modestly reduce cardiovascular events but also may increase the risk of bladder cancer. Rosiglitazone increases the risk of myocardial infarction and has been withdrawn in European and restricted in the United States. Fibrates improve cardiovascular outcomes only in select subgroups: fenofibrate in diabetic patients with metabolic syndrome, gemfibrozil in patients with dyslipidemia, and bezafibrate in patients with diabetes or metabolic syndrome. The cardiovascular safety of the new pan agonist aleglitazar, currently in phase II trials, remains to be determined. The heterogenous effects of peroxisome proliferator-activated receptor agonists to date highlight the importance of postmarketing surveillance. The critical question of why peroxisome proliferator-activated receptor agonists seem to improve cardiovascular risk factors without significantly improving cardiovascular outcomes requires further investigation. Copyright © 2012 Elsevier Inc. All rights reserved.
Sayuri N Friedland, Aaron Leong, Kristian B Filion, Jacques Genest, Iliana C Lega, Salvatore Mottillo, Paul Poirier, Jennifer Reoch, Mark J Eisenberg. The cardiovascular effects of peroxisome proliferator-activated receptor agonists. The American journal of medicine. 2012 Feb;125(2):126-33
PMID: 22269613
View Full Text